Nicolas Ghesquière takes us into the future for Louis Vuitton show in Paris

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-10-07 • Permanent link

Rumors of a looming shift in global health policies have sent shockwaves through the financial markets, with investors scrambling to adjust their portfolios. The World Health Organization's (WHO) first-ever global guidelines on child obesity, released earlier this week, have sparked widespread concern among healthcare providers and pharmaceutical companies. According to a report by Goldman Sachs, the WHO's recommendations are expected to lead to a 40% increase in demand for obesity treatments, resulting in a significant boost to the pharmaceutical industry's revenue.

As the WHO's guidelines take effect, consumers are likely to feel the pinch, with prices for obesity treatments and related products expected to rise significantly. The impact on the broader economy is also likely to be substantial, with estimates suggesting that the global obesity treatment market could reach $150 billion by 2025. This could have far-reaching consequences for companies that rely heavily on the obesity treatment market, including pharmaceutical giants and healthcare providers.

The WHO's guidelines on child obesity are part of a growing trend towards increased awareness and action on public health issues. Since the 1980s, there has been a significant shift in the way governments and healthcare providers approach obesity, with a growing recognition of the need for prevention and early intervention. This shift has been driven by a combination of factors, including increased awareness of the health risks associated with obesity and the development of new treatments and therapies.

As the WHO's guidelines take effect, investors will be watching closely for signs of how the pharmaceutical industry will respond. Will companies be able to meet the increased demand for obesity treatments, or will they struggle to keep up with the growing demand? Additionally, will governments and healthcare providers be able to implement the WHO's recommendations effectively, or will they face significant challenges in terms of resources and infrastructure.